A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies

Trial Profile

A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs Avapritinib (Primary)
  • Indications Systemic mastocytosis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Blueprint Medicines
  • Most Recent Events

    • 22 Feb 2018 Planned number of patients changed from 60 to 65.
    • 10 Dec 2017 According to a Blueprint Medicines media release, the company has selected 300 mg QD as the recommended part two dose (RP2D) for the expansion portion of this trial and continues to enroll patients in the expansion portion of the trial with the goal of generating additional data in 2018.
    • 10 Dec 2017 According to a Blueprint Medicines media release, data from the study will be presented in an oral presentation during the Plenary Scientific Session at the 59th American Society of Hematology Annual Meeting and Exposition (ASH).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top